Biosimilars: Strategic considerations for interchangeability

Biosimilars: Strategic considerations for interchangeability

Lev Gerlovin
Life Sciences | Pharmaceuticals

Lev Gerlovin, Ezra Josephson | Life Sciences

Let’s say interchangeability is a viable regulatory option for manufacturers of biosimilars. Would it always make sense to seek an interchangeability designation from a strategic perspective? Because of the diversity and complexity of product and manufacturer characteristics, there may not be a single optimal strategy, but rather a continuum. Click below to read the article.

Download PDF